Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Omics Session Track 2 October 3 2025
Reporter: Stephen J. Williams, PhD
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
4:20-4:40
- APOE was marker for defining a long term survivor and short term survivor for ovarian cancer patients; the markers were in the stroma
- there is spatial communication between tumor and underlying stroma
- it is imperative to understand how your multiomics equipment images a tumor area before it laser captures and send to the MS system; can lose a lot of tissue and information based on differences in resolution
- many of these multiomics systems are validated for the clinic in EU not US
- multiomics spatial analysis allows you to image protein, metabolite, mRNA expression in the 3 dimensional environment of the tumor (tumor cells and stroma)
- they are making a human tumor atlas
- they say a patient who had tumor went home during COVID and took vaccine but got ill with vaccine; but came back to check tumor and tumor had greatly regressed because prevaccine the tumor was immunologically cold and post COVID vaccine any left over tumor showed great infiltration of immune cells
4:40-4:55
Aruna Ayer, PhD, VP, Multiomics, Innovation and Scientific Affairs, BD Biosciences
- BD Bioscience multiomics platform is modular and can add more omics levels in the platorm
- for example someone wanted to look at T cells
- people have added CRISPR screens on the omics platform
- most people are using single cell spatial omics
- they have a FACS on their platform too so you can look at single cell spatial omics and sort different cellular populations
- very comparative to 10X Genomics platform
- their proteomics is another layer you can add on their platform however with proteomics you can high background notice with spatial proteomics or a limited panel of biomarkers
- Their OMICS Protein One panels are optimized for biology and tumor type.
- get high quality multiomics data and proteomics data but in a 3D spatial format
- developed Cellismo Data Visualization software tool
4:55-5:10
Harsha Gowda, PhD, Senior Principal Scientist, Director, Research & Lab Operations, Signios Bio
Signios Biosciences (Signios Bio) is the US-based arm of MedGenome, a global leader in genetic testing services, genomics research, and drug discovery solutions.
Signios Bio is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. We leverage the power of multiomics—integrating data from genomics, transcriptomics, proteomics, epigenomics, metabolomics, and microbiomics—to gain a comprehensive understanding of disease biology. Our AI-powered bioinformatics platform allows us to efficiently analyze these complex datasets, uncovering hidden patterns and accelerating the development of new therapies and diagnostics.
Through the integration of cutting-edge multiomics technologies, advanced bioinformatics, and the expertise of world-class scientists, we enable researchers and clinicians with comprehensive, end-to-end solutions to improve drug discovery and development and advance precision medicine.
As part of MedGenome, we have access to real-world evidence (RWE) from global research networks across the US, Europe, Asia, Africa, Middle East, and Latin America. This access enables us to work with our partners to uncover insights that can lead to new biomarkers and drug targets, ensuring that precision medicine is inclusive and effective for all.
- their platform can do high throughput analysis of patient tumors (like gallbladder cancer) analyzing mutational spectrum with high dimensionality
- they can integrate genomic and transcriptomics data to reveal multiple pathways affected in patient data
- have used their platform to investigate spatial omics in lung cancer
2012pharmaceutical
sjwilliamspa